Patrizia Popoli

Medicine & Life Sciences

1. Adenosine A2A Receptors 100%
2. Huntington Disease 82%
3. Adenosine 47%
4. Purinergic P1 Receptors 46%
5. tocilizumab 45%
6. Pneumonia 43%
7. Parkinson Disease 33%
8. Amyotrophic Lateral Sclerosis 28%
9. Neurodegenerative Diseases 28%
10. Corpus Striatum 22%
11. Type C Niemann-Pick Disease 21%
12. Respiratory Insufficiency 20%
13. Therapeutics 18%
14. Basal Ganglia 18%
15. 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine 17%
16. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 17%
17. Theoretical Models 17%
18. Italy 16%
19. 3-nitropropionic acid 16%
20. Alzheimer Disease 16%
21. Adenosine A1 Receptor Agonists 16%
22. Synaptic Transmission 15%
23. Purinergic P2X7 Receptors 15%
24. Randomized Controlled Trials 14%
25. Oligodendrocyte Precursor Cells 14%
26. Ischemia 13%
27. Protein Tyrosine Phosphatases 13%
28. Cell Survival 12%
29. Translational Medical Research 12%
30. Central Nervous System 11%
31. Oligodendroglia 11%
32. Regenerative Medicine 11%
33. Adenosine A1 Receptors 11%
34. Pathologic Processes 10%
35. Brain Ischemia 10%
36. High-Throughput Nucleotide Sequencing 10%
37. Oxygen 10%
38. Disease Progression 9%
39. Longevity 9%
40. Neuroglia 9%
41. Multiple Sclerosis 9%
42. 1,3-dipropyl-8-cyclopentylxanthine 9%
43. Neurotransmitter Agents 9%
44. Multicenter Studies 9%
45. Publications 8%
46. Cell Differentiation 8%
47. Niemann-Pick Diseases 8%
48. Aptitude 8%
49. Ligands 7%
50. i-cholesterol 7%